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ABSTRACT: Purpose. To determine the effect of gender on the pharmacokinetics of eslicarbazepine
acetate, a novel voltage-gated sodium channel blocker in the development for the treatment of
epilepsy and bipolar disorder.
Methods. Single-centre, open-label, parallel-group study in 12 female and 12 male healthy
subjects. The study consisted of a single-dose (600mg) period and a multiple-dose (600mg, once-
daily, for 8 days) period, separated by 4 days.
Results. Eslicarbazepine acetate was rapidly and extensively metabolized to eslicarbazepine
(S-licarbazepine), the main active metabolite. Following a single-dose, arithmetic mean eslicarba-
zepine maximum plasma concentrations (Cmax) and area under the plasma concentration-time
curve over 24 h (AUC024) and from 0 to infinity (AUC01) were, respectively, 9.3 mg/ml,
128.5mgh/ml and 171.9 mgh/ml in male subjects and 10.1 mg/ml, 150.1mgh/ml and 205.0mgh/ml
in female subjects. At steady-state, Cmax, AUC024 and AUC01 were 15.5 mg/ml, 207.8mgh/ml and
295.8mgh/ml in male subjects, and 16.8 mg/ml, 214.5mgh/ml and 295.2mgh/ml in female subjects.
Steady-state plasma concentrations were attained at 4 to 5 days of administration in both groups.
Eslicarbazepine Cmax, AUC024 and AUC01 female:male geometric mean ratios (90%CI) were,
respectively, 1.09 (0.94; 1.24), 1.16 (1.00; 1.33) and 1.17 (0.99; 1.38) following single-dose, and 1.10
(0.97; 1.25), 1.04 (0.92; 1.17) and 1.01 (0.88; 1.16) at steady-state.
Conclusion. At steady-state, the pharmacokinetic profile of eslicarbazepine acetate was not
affected by gender. Copyright # 2007 John Wiley & Sons, Ltd.
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Introduction
Eslicarbazepine acetate (BIA 2-093, S-()-10-
acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-
carboxamide) is a new voltage-gated sodium
channel (VGSC) blocker currently being devel-
oped for the treatment of epilepsy and bipolar
disorder. It is chemically related to carbamaze-
pine and oxcarbazepine, but has been specifically
designed to avoid the production of toxic
metabolites and to overcome enantiomeric im-
purity and the production of enantiomers or
diastereoisomers of metabolites and conjugates
without losing pharmacological activity [1].
Eslicarbazepine acetate metabolism varies
significantly among different species. When a
non-chiral method is used, the assay is not able to
distinguish between eslicarbazepine [S-licarbaze-
pine; (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/
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b,f/azepine-5-carboxamide] and its R-enantio-
mer [(R-licarbazepine; (R)-()-10,11-dihydro-10-
hydroxy-5H-dibenz/b,f/azepine-5-carboxa-
mide], and the mixture is reported as BIA 2-005.
In the rat, eslicarbazepine acetate is metabolized
mainly to oxcarbazepine, BIA 2-005 being a
minor metabolite. In the dog, BIA 2-005 and
oxcarbazepine are the major metabolites. In the
mouse, BIA 2-005 is the major metabolite.
Following oral administration in humans, esli-
carbazepine acetate is rapidly and extensively
de-esterified by cytosol hydrolases to eslicarba-
zepine [2], the main active metabolite and plasma
levels of parent drug (eslicarbazepine acetate) are
usually undetectable in the plasma [2–4]. No
cytochrome P450 enzymes are involved in the
metabolism of eslicarbazepine acetate and it
appears that eslicarbazepine acetate does not
undergo auto-induction of its metabolism. Glu-
curonidation appears to be the main eslicarbaze-
pine metabolic pathway.
Eslicarbazepine acetate and metabolites were
tested in several models predictive of antic-
onvulsant efficacy. In the maximal electroshock
seizure (MES) test in the rat, eslicarbazepine
acetate was found to be equally potent to
carbamazepine and more potent than oxcarbaze-
pine, 2 and 4 h after the administration by gastric
tube; 8 h after administration, the drugs were
equipotent. Eslicarbazepine acetate and carba-
mazepine were similarly effective in preventing
development of kindling seizures in kindled rats
(data on file). A phase II placebo-controlled,
randomized, parallel-group clinical trial in pa-
tients with partial epilepsy refractory to one or
two standard anti-epileptic drugs showed that
eslicarbazepine acetate 800mg once-daily is an
effective and well-tolerated dose regimen [5].
Phase III clinical development for the adjunctive
treatment of adult patients with partial epilepsy
disorder is currently ongoing.
The prevalence of epilepsy is similar between
males and females [6], and in clinical practice
anticonvulsants are prescribed to both male and
female patients. In 1993 the Food and Drug
Administration (FDA) issued a guidance docu-
ment requiring the inclusion of both genders in
the clinical development of new drugs and in
1998 the FDA policy was confirmed by a report of
the FDAMA (FDA Modernisation Act) Women
and Minorities Working Group [7], requiring that
new drug applications must include data on
safety and effectiveness by sex. Gender-related
differences in drug response can arise because of
variation in pharmacokinetics or pharmacody-
namics [8]. Although no gender-related differ-
ences have been reported with other VGSC
inhibitors (e.g. oxcarbazepine and carbamaze-
pine), this paper reports the results of an
exploratory assessment of the effect of gender
on the pharmacokinetic profile of eslicarbazepine
acetate following a single dose and at steady-
state of eslicarbazepine plasma concentrations. A
primary analysis of this study showed that age
has no significant effect on the pharmacokinetics
of eslicarbazepine acetate and the results are
published elsewhere [2].
Methods
Study design
This was an open-label, non-randomized, non-
controlled, parallel-group study performed at a
single centre (Scope International Life Sciences
AG, Hamburg, Germany). The trial consisted of
one period (Phase A) during which participants
were administered a single oral 600mg dose of
eslicarbazepine acetate followed by a period
(Phase B) during which participants were give a
once-daily oral 600mg dose for 8 days (days 5–
12). In Phase A, the subjects were admitted to the
unit on day 0 (the day before the dosing) and
remained under clinical supervision until at least
24 h post-dose (day 2); then, they left and
attended the unit in the evening and the morning
of days 3–5 for blood sampling and other study
procedures. Phase B started following the 96 h
post-dose procedures of Phase A (day 5) and
subjects were requested to attend the unit in the
morning of days 5–11 for pre-dose blood sam-
pling for ‘trough’ eslicarbazepine plasma assay
and administration of a 600mg dose of eslicar-
bazepine acetate. On the evening of day 11
subjects were admitted to the unit and the last
dose of eslicarbazepine acetate was administered
on the morning of day 12. Subjects remained
under clinical supervision until the 24 h post-
dose procedures (day 13) and, then, they left and
were requested to attend the unit in the evening
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of day 13 and in the morning of days 14, 15, 16
and 17 for blood sampling and other study
procedures.
Eslicarbazepine acetate immediate release
600mg tablets manufactured by BIAL (S. Mamede
do Coronado, Portugal) in accordance with Good
Manufacturing Practice were used. On days 1 and
12, participants were administered their 600mg
dose between 0800 and 0900h with 200ml of
potable water. On those study days, participants
fasted from at least 8 h before until 4 h post-dose.
The study was conducted according to the
principles of the Declaration of Helsinki and the
Good Clinical Practice. An Independent Ethics
Committee (Ethik-Kommission der A¨rztekam-
mer Hamburg, Germany) reviewed and ap-
proved the protocol before the study started
and all participants gave their written informed
consent prior participation.
Study population
Participants enrolled were healthy male or
female volunteers aged 18 to 40 years inclusive
(young group) or 65 years or more (elderly),
within 15% (if young) or 20% (if elderly) of ideal
body weight, non-smokers or smokers of less
than 10 cigarettes or equivalent per day. Female
subjects were surgically sterilized or post-meno-
pausal, or were required to be using double-
barrier or intrauterine device contraception
methods. Subjects were required to abstain from
taking any medication within 2 weeks prior
admission and no concomitant medication was
allowed during the study unless required for
treatment of adverse events.
Twelve females [6 young (mean age SD:
30.0 7.4 years, range: 21–38 years; weight
61:8 10:7 kg, range: 48:0273:0 kg) and 6 elderly
(69:8 5:3 years, range: 65–80 years; weight
67:7 9:1 kg, range: 55:0282:5 kg)]; and 12 males
[6 young (29:7 7:4 years, range: 18–36 years;
weight 78:3 10:5 kg, range: 66:0298:0 kg) and 6
elderly (70:0 6:0 years, range: 65–79 years;
weight 86:0 9:5 kg, range: 76:02103:5 kg)] com-
pleted the study according to the protocol.
Plasma drug assay
Blood samples (7ml of venous blood) were
collected at the following times: pre-dose, and
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 h
after the dose of eslicarbazepine acetate, on day
1; before the daily dose, on days 5–11 of Phase B;
pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48,
72, 96 and 120 h post-dose, on day 12. Blood
samples were collected into tubes containing
lithium heparin anticoagulant and centrifuged at
approximately 1500g for 10min at 48C. The
resulting plasma was separated into two equal
aliquots of 1ml and stored at –208C until
required for analysis.
Plasma concentrations of eslicarbazepine acet-
ate were determined using isocratic liquid
chromatography (LC) with single quadrupole
mass spectrometric detection (MS).
The method involved the addition of 500 ml of
approximately 0.5 mg/ml of 10,11-dihydrocarba-
mazepine (internal standard prepared in acetoni-
trile:water, 3:97, v:v) to 250 ml of plasma
(centrifuged at 450g, prior to analysis) in a
polypropylene tube. After vortex mixing for
10 s, the mixture was transferred to a Schleicher
and Schuell C18/100mg 96-well solid phase
extraction plate. Each well was preconditioned
with 800 ml methanol, followed by 800 ml acetoni-
trile and 800 ml acetonitrile:water, 3:97, v:v, prior
to application of the total sample volume. Each
polypropylene tube was then washed with 500 ml
acetonitrile:water, 3:97, v:v and the washings
transferred to the respective well. The com-
pounds were eluted into a collection plate with
750 ml acetonitrile and the extract evaporated to
dryness under oxygen-free nitrogen, at 408C. All
solid phase extraction manipulations were un-
dertaken using the Tomtec QUADRA 961 Model
320 system and a vacuum was applied at each
elution step. The final extract was reconstituted
in 100 ml of water:methanol (90:10, v:v) and
mixed. The collection plate was then centrifuged
at approximately 1000g (at approximately 48C,
for approximately 10min) prior to analysis. An
aliquot of the final extract (10 ml) was injected
onto the LC-MS system.
The LC-MS system used in the analysis
consisted of a Perkin Elmer series 200 micro
pump, a Perkin Elmer series 200 autosampler, a
Perkin Elmer/Sciex API 150EX single quadru-
pole mass spectrometer fitted with a Turbo
IonSpray1 source. Separation was achieved
using a LichroCART 250-4 ChiraDex analytical
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column (b-cyclodextrin, 5 mm), a LichroCART 4-4
ChiraDex guard column (b-cyclodextrin, 5 mm), a
Jones chromatography 7971 column heater at
508C, a mobile phase A (0.2mM sodium acetate,
aq) and a mobile phase B (0.2mM sodium
acetate, MeOH). The MS detector was operated
in positive ion mode with mass transitions for
eslicarbazepine and the internal standard of
277.08 amu (200ms) and 261.05 amu (200ms),
respectively.
Calibration curves over the nominal concen-
tration range 100–10000 ng/ml and a set of
quality control (QC) samples (triplicates over 3
concentration levels: 200, 4000 and 8000 ng/ml)
were analysed with each batch of study samples.
The QC samples were used to monitor the
performance of the assay. The data for the QC
samples showed that the overall imprecision of
the method, measured by the coefficient of
variation, ranged from 6.7% to 9.6%. The mean
accuracy ranged from 98.1% to 102.8% and the
limit of quantification of the assay was 100 ng/
ml.
Eslicarbazepine was synthesized in the La-
boratory of Chemistry, BIAL, with a purity of >
99.9%. The internal standard, 10,11-dihydrocar-
bamazepine was supplied by Sigma-Aldrich (St
Louis, MO).
Pharmacokinetic and statistical evaluation
The following eslicarbazepine pharmacokinetic
parameters were derived from the individual
plasma concentration-time profiles using non-
compartmental analysis (WinNonlin, Version 4.0,
Pharsight Corporation, Mountain View, CA):
maximum observed plasma concentration (Cmax),
time of occurrence of Cmax (tmax), area under the
plasma concentration versus time curve (AUC)
from time zero to the last sampling time at which
concentrations were at or above the limit of
quantification (AUC0t, calculated by the linear
trapezoidal rule), AUC over the 24 h dosing
interval (AUCt), AUC from time zero to infinity
(AUC01, calculated from AUC0t + Clast/lz,
where Clast is the last quantifiable concentration
and lz is the apparent terminal rate constant); lz
was calculated by log-linear regression of the
terminal segment of the plasma concentration
versus time curve. The apparent terminal half-life
(t1/2) was calculated from ln 2/lz, the observed
degree of accumulation (R0) was calculated from
AUC01 (day 12)/AUC01 (day 1) and the
theoretical degree of accumulation (RT) was
calculated from 1/(1explzt), where t is the
dosing interval.
The rate and extent of systemic exposure to
eslicarbazepine following single-dose and multi-
ple-dose administration of eslicarbazepine acet-
ate to female and male subjects was compared
through the geometric mean ratios (GMR)
and the corresponding 90% confidence intervals
(90%CI) of eslicarbazepine Cmax, AUCt (24 h)
and AUC01. The adopted test procedure is
analogous to equivalence testing. The pharmaco-
kinetic parameters were logarithmically trans-
formed prior to analysis. In accordance with
the guidelines for bioequivalence testing, the
bioequivalence can be assumed when the
geometric mean ratio lies within the 90%CI
0.80–1.25 [9,10].
A tmax comparison between gender groups was
performed assuming a non-parametric approach
using the Wilcoxon signed rank test (untrans-
formed values). All tests of significance were
performed at the p ¼ 0:05 level.
In a previous study [11], reported intra-subject
variability of AUC and Cmax was lower than 15%.
Assuming an intra-subject variability of 15%, a
GMR of 1.0 and a a ¼ 0:05 (two-tailed), a sample
size of n ¼ 24 subjects would provide at least
80% probability that the 90% CI are contained
within the interval commonly used for accepting
bioequivalence (0.80–1.25) [9,10].
All statistical analyses were performed using
the statistical package SAS (Version 8.2, SAS
Institute Inc, Cary, NC).
Results
Figures 1 and 2 display the mean eslicarbazepine
concentration-time profiles in the male and
female groups. The eslicarbazepine pharmacoki-
netic parameters in the male and female groups
following a 600mg single-dose of eslicarbazepine
acetate (Phase A) and following the last dose of a
600mg once-daily regimen for 8 days (Phase B)
are presented in Table 1. The mean ‘trough’
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Figure 1. Mean eslicarbazepine plasma concentration-time
profiles in the male and female groups following oral
administration of a 600mg single-dose of eslicarbazepine
acetate (Phase A) (n ¼ 12 in each gender group): (a) linear
scale and (b) semi-log scale
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Figure 2. Mean eslicarbazepine plasma concentration-time
profiles in the male and female groups following the last dose
of a 600mg once-daily regimen of eslicarbazepine acetate for 8
days (Phase B) (n ¼ 12 in each gender group): (a) linear scale
and (b) semi-log scale
Table 1. Eslicarbazepine pharmacokinetic parameters following a single-dose of 600mg of eslicarbazepine acetate and following
the last dose of a 600mg once-daily regimen of eslicarbazepine acetate for 8 days in the female and male groups (n ¼ 12 in each
gender group)
Parameter Female Male
Single-dose Multiple-dose Single-dose Multiple-dose
Cmax (mg/ml) 10.1 (2.3) 16.8 (2.0) 9.3 (1.7) 15.5 (3.7)
tmax (h) 3.0 (2–6) 2.0 (1–6) 2.0 (1–6) 1.3 (1–4)
AUCt (mgh/ml) 150.1 (36.8) 214.5 (30.0) 128.5 (22.1) 207.8 (40.8)
AUC01 (mgh/ml) 205.0 (67.5) 295.2 (44.4) 171.9 (34.2) 295.8 (65.0)
t1/2 (h) 10.3 (0.95) 10.4 (1.0) 10.7 (1.1) 11.2 (1.8)
Results are expressed as arithmetic means with corresponding standard deviations in parentheses; tmax values are median with range values in
parentheses.
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(pre-dose) concentrations during Phase B (days
5–12) are presented in Table 2.
Following a 600mg single-dose of eslicarbaze-
pine acetate (Phase A), Cmax of eslicarbazepine
was reached (tmax) at 3.0 h (median) in the female
group and 2.0 h in the male group. Thereafter,
plasma concentrations declined in a multiphasic
manner with a mean apparent t1/2 of 10.3 h and
10.7 h, respectively.
In Phase B (multiple-dose period), the steady-
state of eslicarbazepine plasma concentrations
was attained at 4 to 5 days of administration in
both gender groups, consistent with an effective
half-life in the order of 14.0 h (female) and 19.1 h
(male), calculated from the theoretical degree of
accumulation (RT) where lz is the key value for
its determination (t1=2 eff ¼ ln 2=lz) in accordance
with Boxenbaum and Battle [12]. An observed
accumulation factor (R0) of 1.44 (female) and 1.72
(male) was estimated.
Following the last dose of Phase B, Cmax of
eslicarbazepine was reached (tmax) at 2.0 h (med-
ian) in the female group and 1.3 h in the male
group and, thereafter, plasma concentrations
declined in a multiphasic manner with a t1/2 of
10.4 and 11.2 h, respectively.
The GMR and corresponding 90%CI of esli-
carbazepine Cmax, AUCt (24 h) and AUC01 are
displayed in Table 3. Following single-dose
administration of eslicarbazepine acetate, the
90%CI for AUC01 and AUCt are not contained
within the acceptance 0.80–1.25 interval [9,10]
and the extent of systemic exposure to eslicarba-
zepine following single-dose administration in
female subjects can be assumed to be higher than
that observed in male subjects. Following admin-
istration of eslicarbazepine acetate at steady-
state, the 90%CIs are contained within the 0.80–
1.25 interval for the parameters compared
(AUC01, AUCt and Cmax) and, therefore, both
rate and extent of systemic exposure to eslicar-
bazepine can be considered similar in both
gender groups. The statistical power for
AUC01, AUCt and Cmax was 0.85, 0.92 and
0.89, respectively.
Eslicarbazepine apparent clearance (CL=F ¼
dose=AUC) was higher in the female group when
corrected for difference in body weight. Follow-
ing eslicarbazepine acetate single-dose, a (CL/
F)/weight value of 48.6ml/h/kg and 44.1ml/h/
kg was obtained in the female and the male
groups, respectively, corresponding to a female/
Table 2. ‘Trough’ (pre-dose) eslicarbazepine plasma concentrations during an oral 600mg once-daily regimen of eslicarbazepine
acetate for 8 days in the male and female groups (n ¼ 12 in each gender group)
Group Trough eslicarbazepine concentrationsa (mg/ml)
Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12
Female BLQ 3.6 (0.9) 4.6 (1.6) 5.1 (1.6) 5.5 (1.9) 5.4 (1.7) 5.9 (1.8) 5.3 (1.5)
Male BLQ 3.1 (0.6) 4.6 (1.0) 5.6 (1.3) 5.7 (1.3) 6.0 (1.7) 5.6 (1.4) 5.3 (1.5)
Results are expressed as arithmetic means with corresponding standard deviations in parentheses. BLQ}below the limit of quantification of the
assay (0.1 mg/ml).
aRepeated dose administration started at day 5.
Table 3. Eslicarbazepine geometric mean Cmax, AUCt and AUC01 and respective female:male ratios following a 600mg single-
dose and a 600mg once-daily regimen of eslicarbazepine acetate for 8 days (n ¼ 12 in each gender group)
Female group Male group Ratio female/male 90%CI
Cmax (mg/ml) Single-dose 9.9 9.1 1.09 0.94; 1.24
Multiple-dose 16.7 15.2 1.10 0.97; 1.25
AUCt (mgh/ml) Single-dose 146.5 126.7 1.16 1.00; 1.33
Multiple-dose 249.9 204.1 1.04 0.92; 1.17
AUC01 (mgh/ml) Single-dose 197.2 168.8 1.17 0.99; 1.38
Multiple-dose 292.0 289.0 1.01 0.88; 1.16
A. FALCA˜O ET AL.254
Copyright # 2007 John Wiley & Sons, Ltd. Biopharm. Drug Dispos. 28: 249–256 (2007)
DOI: 10.1002/bdd
male ratio of 1.10. At steady-state, (CL/F)/weight
was respectively 32.5ml/h/kg and 26.1ml/h/
kg, with a female/male ratio of 1.25.
No statistical differences between gender
groups were found in tmax, following single-dose
(p ¼ 0:153) and multiple-dose (p ¼ 0:085) admin-
istration.
Discussion and Conclusion
In previous studies eslicarbazepine acetate was
shown to be extensively metabolized to eslicar-
bazepine and plasma concentrations of parent
drug were systematically found to be below the
limit of quantification [2–4]. Data from that study
showed that age has no significant effect on the
pharmacokinetics of eslicarbazepine acetate [2].
The present study reports further analyses on the
effect of gender on the pharmacokinetics of this
new VSGC inhibitor.
Failure to analyse gender-related differences
in pharmacokinetics, adverse event profiles
and efficacy of new medications limit the gen-
eralizability of such data to women. Gender-
related behaviour regarding drug disposition
is an important issue in epilepsy and bipolar
disorder, indications in which eslicarbazepine
acetate is being developed, because women
represent at least half of these patient popula-
tions [6,13]. Evidence of gender-related differ-
ences in pharmacokinetics abounds, but the
mechanisms involved are complex and often
poorly understood. The mechanistic processes
underlying gender-specific pharmacokinetics can
be divided into molecular and physiological
factors [14]. Molecular factors include
drug transporters and drug-metabolizing en-
zymes and the physiological factors include the
lower weight and organ size, higher percentage
of fat, lower glomerular filtration rate and
different gastric motility in women compared
with men [14].
In the present study, the results of single-dose
and steady-state pharmacokinetics in 12 female
and 12 male subjects were compared. Each
gender group was composed of 6 young and 6
elderly subjects. Female and male groups did not
differ regarding mean age (49:9 21:7 years and
49:8 22:0 years, respectively) but, as expected,
a difference was found in their mean weights
(64:7 9:9 kg and 82:2 10:4 kg, respectively).
This 21.3% lower weight in females could justify
a corresponding difference in the main pharma-
cokinetic parameters assessed. Following single-
dose and multiple-dose, the rate of systemic
exposure to eslicarbazepine, as assessed by Cmax,
was 9% and 10% higher in females when
compared with males (GMR 1.09 and 1.10,
respectively). Using the bioequivalence ap-
proach, the 90%CIs fall within the acceptance
interval 0.80–1.25. The extent of systemic expo-
sure to eslicarbazepine, as assessed by AUCt and
AUC01, was 16% and 17% higher following
single dose and 4% and 1% higher following
multiple dose, in females when compared with
males. Using the equivalence approach, the
90%CI fall within the acceptance interval 0.80–
1.25 following administration at the steady state,
but do not fulfil the bioequivalence criteria
following single-dose. However, the product is
aimed to be used chronically and, therefore, the
relatively slight (although statistically significant)
gender difference following single-dose is not
foreseen to be of clinical significance.
Differences in absorption, distribution, meta-
bolism and excretion may account for gender-
related pharmacokinetic differences [14]. In the
present study, the time to maximum plasma
eslicarbazepine concentration occurred later in
women than men (although the difference did
not attain statistical significance), which is in line
with the reported slower gastric emptying
observed in females when compared with male
subjects [14].
A faster apparent clearance in women in
comparison with men (female/male ratio of
1.25, at steady-state) was reported in this study.
The main metabolic steps involved in the
metabolism of eslicarbazepine acetate and esli-
carbazepine are, respectively, de-esterification by
cytosol hydrolases (mainly in the liver) and
glucuronidation by uridine 5-diphosphate glu-
curonosyltransferase (UGT). A faster eslicarbaze-
pine glucuronidation in women is not expected
to occur because UGTactivity has been suggested
to be lower in women compared with men [14].
Therefore, it is not expected that differences in
de-esterification and subsequent glucuronidation
of eslicarbazepine acetate may account for the
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faster eslicarbazepine clearance observed in
women.
Glomerular filtration rate is usually 10% lower
in women than men and gender-related differ-
ences in tubular secretion and tubular reabsorp-
tion may occur, but have not been well
characterized [14]. Non-clinical data have sug-
gested that eslicarbazepine may undergo tubular
reabsorption [data on file]. It might be hypothe-
sized that a lower tubular reabsorption rate could
be responsible for an apparently higher clearance
in women, but differences between males and
females at this level have not yet been evaluated.
Although a slight trend for higher values in the
pharmacokinetic parameters related to systemic
exposure were reported in the female group
compared with the male group, differences were
not proportional to the 21.3% lower body weight
in females. The faster apparent clearance in
women in comparison to men may compensate,
at least partially, the lower body weight effect on
the pharmacokinetic parameters, resulting in
relatively similar values in both genders. No
pharmacokinetic gender-related differences were
observed with oxcarbazepine, a compound che-
mically related to eslicarbazepine acetate [15].
In conclusion, gender-related differences in
systemic exposure to eslicarbazepine were slight
and non-significant and unlikely to be relevant in
clinical practice and can be explained by the
demographic characteristics such as the higher
mean weight observed in the male group in
comparison with the female group. Therefore,
dose-adjustments of eslicarbazepine acetate
based on gender will not be required.
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